User profiles for "author:Natasha Woodward"

Natasha Woodward

Senior Medical Oncologist, Associate Professor
Verified email at mater.org.au
Cited by 1612

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies

GY Ho, N Woodward, JIG Coward - Critical reviews in oncology …, 2016 - Elsevier
The platinum analogues, cisplatin and carboplatin, are among the most widely used
chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity …

[HTML][HTML] Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

CE Geyer Jr, JE Garber, RD Gelber, G Yothers… - Annals of oncology, 2022 - Elsevier
Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early breast cancer: a systematic review and meta-analysis

K Roberts, K Rickett, R Greer, N Woodward - Critical Reviews in Oncology …, 2017 - Elsevier
Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor
positive breast cancers in the post-menopausal population. AI are often associated with …

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with …

JL Hare, JK Brown, R Leano, C Jenkins… - American heart …, 2009 - Elsevier
BACKGROUND: Trastuzumab prolongs survival in patients with human epidermal growth
factor receptor type 2–positive breast cancer. Sequential left ventricular (LV) ejection fraction …

Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer

KE Roberts, K Rickett, S Feng… - Cochrane Database …, 2020 - cochranelibrary.com
Background Survival for stage I to III, hormone receptor‐positive, breast cancer has
substantially improved over time due to advances in screening, surgery and adjuvant …

Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy

HS Rugo, J Ettl, SA Hurvitz, A Gonçalves… - JNCI cancer …, 2020 - academic.oup.com
Background Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor that
causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations …

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

C Lemech, N Woodward, N Chan, J Mortimer… - Investigational New …, 2020 - Springer
ABBV-176 is an antibody-drug conjugate composed of the humanized antibody h16f (PR-
1594804) conjugated to a highly potent, cytotoxic cross-linking pyrrolobenzodiazepine …

[HTML][HTML] Poor muscle status, dietary protein intake, exercise levels, quality of life and physical function in women with metastatic breast cancer at chemotherapy …

J Parkinson, A Bandera, M Crichton, C Shannon… - Current …, 2023 - mdpi.com
This study aimed to investigate nutritional status, body composition, dietary protein intake,
handgrip strength, 6 min or 4 m walk tests, self-reported physical activity, physical function …

[HTML][HTML] Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone …

CE Snell, M Gough, C Liu, K Middleton, C Pyke… - British Journal of …, 2018 - nature.com
Background Recent pre-clinical studies indicate that activated progesterone receptor
(PR)(particularly the PR-B isoform) binds to oestrogen receptor-α (ER) and reprogrammes …

Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer

R Ladwa, T Kalas, S Pathmanathan, N Woodward… - Clinical breast …, 2018 - Elsevier
Introduction Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at≥
85% has been associated with improved treatment outcomes in early-stage breast cancer …